Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Meeting Highlights
Lung Cancer
,
ASCO Highlights
Atezolizumab Extends Disease-Free Survival in PD-L1−Positive Early-Stage NSCLC
Phoebe Starr
Phoebe Starr
Read More
Lung Cancer
2021 Midyear Review: Non–Small-Cell Lung Cancer
Read More
Case Reports
,
Lung Cancer
,
Adverse Events
,
Chemotherapy
Facial Edema Preceding Acute Renal Injury Linked to Pemetrexed Therapy in a Patient with Lung Cancer
Matthew S. Mattila, PharmD, BCPS, BCOP
,
Joel M. Lundberg, MD, FACP
Matthew S. Mattila, PharmD, BCPS, BCOP; Joel H. Lundberg, MD, FACP
Read More
FDA Oncology Update
,
Lung Cancer
Lorbrena Now FDA Approved for First-Line Treatment of Metastatic NSCLC
Read More
FDA Oncology Update
,
Lung Cancer
FDA Approves Tepmetko for Metastatic NSCLC and MET Exon 14 Skipping Alterations
Read More
FDA Oncology Update
,
Lung Cancer
Tagrisso Receives New Indication as Adjuvant Therapy for NSCLC with EGFR Mutations
Read More
Lung Cancer
Patients with BRAF V600E–Mutant NSCLC Show Improved Overall Survival with Dabrafenib + Trametinib Combination
Read More
Lung Cancer
GEOMETRY Mono-1 Results: Capmatinib for the Treatment of MET Exon 14–Mutated NSCLC
Read More
Lung Cancer
Ramucirumab plus Erlotinib in the Treatment of Patients with NSCLC with EGFR Exon 19 or Exon 21 Mutations
Read More
Lung Cancer
First-Line Treatment with Lorlatinib Improves Outcomes Over Crizotinib in Patients with ALK-Positive NSCLC
Read More
1
2
3
4
5
6
7
Page 4 of 12
Results 31 - 40 of 114